CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a research note released on Friday morning. The firm issued a sell rating on the stock.

CEL-SCI Price Performance

Shares of CVM stock opened at $0.22 on Friday. The stock’s 50-day moving average is $0.25 and its 200 day moving average is $0.42. CEL-SCI has a 1-year low of $0.18 and a 1-year high of $2.22. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.07 and a quick ratio of 1.09. The company has a market cap of $18.76 million, a P/E ratio of -0.46 and a beta of 0.50.

Institutional Investors Weigh In On CEL-SCI

A hedge fund recently raised its stake in CEL-SCI stock. Thoroughbred Financial Services LLC raised its holdings in shares of CEL-SCI Co. (NYSE:CVM) by 40.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 191,661 shares of the company’s stock after purchasing an additional 54,900 shares during the period. Thoroughbred Financial Services LLC owned 0.26% of CEL-SCI worth $76,000 at the end of the most recent quarter. 12.08% of the stock is owned by hedge funds and other institutional investors.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.